Helping our customers to do the right business in the right way

2024 Results

Revenue for the year

£126.0m

+2%

Adjusted EBITA

£25.6m

+6%

Adjusted profit before tax

£27.6m

+13%

Organic revenue growth

9%

2023: 13%

Adjusted PBT margin

20%

2023: 20%

Profit before tax 

£48.5m

2023: £24m

Adjusted earnings per share

22.96p

+7%

Total dividend

11.3p

+13%

Group net cash excl. lease liabilities

£67.8m

+61%

Basic earnings/(loss) per share

45.92p

2023: 22.94p

Final dividend

8.3p

2023: 7.3p

Cash conversion at

116%

2023: 138%

Chief Executive's Statement

Mark Milner
speech marks

We have delivered another strong year, in line with our strategy with notably strong increases in revenues, profits and cash generation. Margins have also continued to improve strongly.  We continued to focus on consolidating our already strong presence in the large, growing and rapidly evolving international GRC markets and significantly enhanced our capabilities with the acquisition of Astutis in the Health, Safety and Environment (‘HSE’) sector. We sold our European Healthcare businesses and MiExact. We now have a higher quality portfolio of growing international businesses and continue to pursue various opportunities to invest in acquisitions to improve our growth and profitability. We have also started to transfer our businesses onto our single operating platform, which will continue to improve our performance. We have had a good start to the current financial year, with revenues and profits in line with expectations.

Mark Milner

Chief Executive Officer

 

 

Downloads